nach oben

International Journal of Clinical Oncology

Erschienen in:

07.03.2019 | Review Article

Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.

Toyoda Y, Nakayama T, Ioka A et al (2008) Trend in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 38:534–539CrossRefPubMedPubMedCentral

National Cancer Institute: SEER Cancer Statistics Review: Available via DIALOG https://seer.cancer.gov/. Accessed May 2018

Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852–3859CrossRefPubMed

Hotta K, Matsuo K, Ueoka H et al (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15:1782–1789CrossRefPubMed

Hotta K, Matsuo K (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2:96CrossRefPubMed

Hotta K, Fujiwara Y, Matsuo K et al (2007) Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109:939–948CrossRefPubMed

Hotta K, Takigawa N, Hisamoto-Sato A et al (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43:1115–1123CrossRefPubMed

Ninomiya K, Hotta K, Hisamoto-Sato A et al (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21:81–87CrossRefPubMed

Hotta K, Ninomiya K, Takigawa N et al (2015) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol 45:603–604PubMed

10.

Hotta K, Sekine I, Tamura T et al (2001) A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 31:596–600CrossRefPubMed

11.

Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551CrossRefPubMed

12.

Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191CrossRefPubMed

13.

Shukuya T, Yamanaka T, Seto T et al (2015) Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol 16:1630–1638CrossRefPubMed

14.

Thatcher N, Hirsch FR, Luft AV et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763–774CrossRefPubMed

15.

Yoshioka H, Watanabe S, Sakai H et al (2018) Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): an open-label randomized multicenter phase Ib-II trial in Japan. ASCO 2018 (Abs 9038)

16.

Hotta K, Kiura K, Tabata M et al (2014) A Survey of Japanese thoracic oncologists’ perception of diagnostic and treatment strategies for EGFR-mutant or EML4-ALK-fusion non-small cell lung cancer. Chest 146:e222–e225CrossRefPubMed

17.

Hotta K, Kiura K, Toyooka S et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2:632–637CrossRefPubMed

18.

Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943–950CrossRefPubMed

19.

Hotta K, Kato Y, Leighl N et al (2015) Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer. Syst Rev PLoS One 10:e0121211CrossRef

20.

Kudo K, Hotta K, Ichihara E et al (2015) Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemother Pharmacol 76:251–256CrossRefPubMed

21.

Kudo K, Hotta K, Bessho A et al (2016) Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small-cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 77:1005–1009CrossRefPubMed

22.

Isozaki H, Hotta K, Ichihara E et al (2016) Protocol design for the bench to bed trial in alectinib-refractory non-small-cell lung cancer patients harboring the EML4-ALK fusion gene (ALRIGHT/OLCSG1405). Clin Lung Cancer 17:602–605CrossRefPubMed

23.

Tamura T, Kato Y, Ohashi K et al (2018) Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochem Biophys Res Commun 495:360–367CrossRefPubMed

24.

Oda N, Hotta K, Yoshioka H et al (2016) Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 78:941–947CrossRefPubMed

25.

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388CrossRefPubMed

26.

Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125CrossRefPubMed

27.

Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer.N. Engl J Med 371:2167–2177CrossRef

28.

Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39CrossRefPubMed

29.

Bui KT, Cooper WA, Kao S et al (2018) Targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists. J Clin Med 7:pii: E192. https://doi.org/10.3390/jcm7080192 CrossRef

30.

Shukuya T, Takahashi T, Kaira R et al (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102:1032–1037CrossRefPubMed

31.

Japanese Lung Cancer Society (2017) EBM no shuho ni yoru haigan shinryo guideline. Kanehara &Co. Ltd., Tokyo

32.

Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer. A cohort and nested case–control study. Am J Respir Crit Care Med 177:1348–1357CrossRefPubMed

33.

Hotta K, Kiura K, Takigawa N et al (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 5:179–184CrossRefPubMed

34.

Hotta K, Kiura K, Tabata M et al (2005) Interstitial lung disease in patients with non-small-cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 11:417–424CrossRefPubMed

35.

Reck M, Rodriguez-Abreu D, Robinson AG, KEYNOTE-024 Investigators et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRefPubMed

36.

Brahmer JR, Rodríguez-Abreu D, Robinson AG et al (2017) Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 18:1600–1609CrossRefPubMed

37.

Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. J Clin Oncol. https://doi.org/10.1200/JCO.18.00149 (epub ahead of print) CrossRefPubMedPubMedCentral

38.

Lopes G, Wu YL, Kudaba I et al (2018) Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. ASCO 2018 (Abs LBA4)

39.

Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040–2051CrossRefPubMed

40.

Jotte RM, Cappuzzo F, Vynnychenko I et al (2018) IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. ASCO 2018 (Abs LBA9000)

41.

Socinski MA, Rittmeyer A, Shapovalov D et al (2018) IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. ESMO 2018

42.

Govindan R, Szczesna A, Ahn MJ et al (2017) Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35:3449–3457CrossRefPubMed

43.

Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 31:2093–2104CrossRef

44.

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135CrossRefPubMedPubMedCentral

45.

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRefPubMed

46.

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMed

47.

Gadgeel S, Kowanetz F, Zou W et al (2017) Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: results from the randomized OAK study. ESMO 2017 (Abs 1296O)

48.

Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefPubMed

49.

Nokihara H, Lu S, Mok TSK et al (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28:2698–2706CrossRefPubMedPubMedCentral

50.

Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218CrossRefPubMedPubMedCentral

51.

Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633–641CrossRefPubMedPubMedCentral

52.

Cyriac G, Gandhi L (2018) Emerging biomarkers for immune checkpoint inhibition in lung cancer. Semin Cancer Biol 52:269–277CrossRefPubMed

53.

Curran MA, Montalvo W, Yagita H et al (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280CrossRefPubMedPubMedCentral

54.

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34CrossRefPubMedPubMedCentral

55.

Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30700-9 (epub ahead of print) CrossRefPubMed

56.

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290CrossRefPubMedPubMedCentral

Titel: Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan
Publikationsdatum: 07.03.2019
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01424-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival

Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy

Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer

Clinical factors associated with the therapeutic outcome of chemotherapy in very elderly cancer patients

A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie